A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts.
Completion rates, total cost, and adverse effects were compared for patients in central Massachusetts treated for latent tuberculosis infection with 9 months of isoniazid or 4 months of rifampin. Although the adverse effects were similar between the 2 groups, 4 months of rifampin was associated with significantly better completion rates and less hepatotoxicity yet higher total cost.
Young
Heather
H
Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
Wessolossky
Mireya
M
Ellis
Jeanne
J
Kaminski
Martin
M
Daly
Jennifer S
JS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D008297:Male; D008404:Massachusetts; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data*; D012293:Rifampin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy* / Q000191:economics*; D055815:Young Adult
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin